SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-338188
Filing Date
2018-11-29
Accepted
2018-11-29 17:13:05
Documents
5
Period of Report
2018-12-20
Effectiveness Date
2018-11-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A d647608ddef14a.htm DEF 14A 335573
2 GRAPHIC g647608g10k34.jpg GRAPHIC 166512
3 GRAPHIC g647608g19l69.jpg GRAPHIC 243911
4 GRAPHIC g647608g22h44.jpg GRAPHIC 32876
5 GRAPHIC g647608g30c53.jpg GRAPHIC 45469
  Complete submission text file 0001193125-18-338188.txt   994852
Mailing Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511
Business Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511 312 767 0291
MELINTA THERAPEUTICS, INC. /NEW/ (Filer) CIK: 0001461993 (see all company filings)

IRS No.: 454440364 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35405 | Film No.: 181209150
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences